Tepotinib (Tepmetko)

General information

Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Non-small cell lung cancer, MET-mutated

Patient drug information

• Tepotinib (Tepmetko) package insert
• Tepotinib (Tepmetko) patient drug information (UpToDate)

History of changes in FDA indication

• 2/3/2021: Granted accelerated approval for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. (Based on VISION_NSCLC)

Also known as

• Code names: EMD-1214063, MSC-2156119, MSC-2156119J
• Brand name: Tepmetko